Program
TQC2938
A development code. Also written as “TQC2938 injection” and “TQC2938 Injection”.
In Sino Biopharmaceutical's pipeline, ST2 (IL-33R) 单抗
. Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Asthma, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 32 open or running | phase 2since Jan 17, 2025 | Jun 3, 2024 | Mar 17, 2027phase 2 · NCT06789289 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQC2938
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 3, 2024First study: phase 1 study in AsthmaFirst studyNCT06449859 · 84 enrolled · China
- Jan 17, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06789289 · 256 enrolled · China
- Jun 8, 2025Phase 2 study in Rhinitis, Allergic, SeasonalNCT07052097 · 136 enrolled · China
Ahead
- Mar 17, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06789289
TargetBeta
“ST2 (IL-33R) 单抗”the company's pipeline, read by Claude · source
Other programs on IL33R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| astegolimab | Hoffmann-La Roche | phase 3 | 9 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07052097Rhinitis, Allergic, Seasonal · China | 2 | Completed | Sep 12, 2025 | 136 |
| NCT06789289Pulmonary Disease, Chronic Obstructive · China | 2 | Active, not recruiting | Mar 17, 2027 | 256 |
| NCT06449859Asthma · China | 1 | Active, not recruiting | Nov 2024 | 84 |
How it is read
Names in the registry
- “TQC2938 injection”, 2 entries
- “TQC2938 Injection”, 1 entry
Codes read as this program: TQC2938.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 1 study
- Rhinitis, Allergic, Seasonal, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.